Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients

Rishi Sukhija, Sastry Prayaga, Mohammad Marashdeh, Zoran Bursac, Priyanka Kakar, Darpan Bansal, Rajesh Sachdeva, Sree Hari Kesan, Jawahar L. Mehta

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Background: The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) reduce serum cholesterol level and cardiovascular morbidity and mortality. However, the effect of statins on glucose metabolism is unclear. Some studies have suggested that statins may cause hyperglycemia by increasing calcium concentration in the islet cells leading to decrease in insulin release or by decreasing GLUT 4-mediated peripheral glucose uptake. Methods: We analyzed the data in 345,417 patients (mean age 61 ± 15 years, 94% males, 6% diabetic, 20% statin users) from the Veterans Affairs VISN 16 database. We studied change in fasting plasma glucose (FPG) in this population over a mean time of 2 years between the first available measurement and the last measurement form the most recent recorded visit. Data were limited to patients who had 2 FPG measurements. Diagnosis of diabetes had to be present before the first FPG measurement. Results: Among patients without diabetes, FPG increased with statin use from 98 mg/dL to 105 mg/dL, and among nonstatin users, FPG increased from 97 mg/dL to 101 mg/dL (increase in FPG with statin use P < 0.0001). Among patients with diabetes, FPG increased with statin use from 102 mg/dL to 141 mg/dL, and among nonstatin users, FPG increased from 100 mg/dL to 129 mg/dL (increase in FPG with statin use; P < 0.0001). After adjustment for age and use of aspirin, β-blockers, and angiotensin-converting enzyme inhibitors, the change in FPG in nondiabetic statin users was 7 mg/dL (vs 5 mg/dL in nonstatin users, P < 0.0001) and for diabetic statin users it was 39 mg/dL (vs 32 in nonstatin users, P < 0.0001). Conclusions: Statin use is associated with a rise of FPG in patients with and without diabetes. This relationship between statin use and rise in FPG is independent of age and use of aspirin, β-blockers, and angiotensin-converting enzyme inhibitors.

Original languageEnglish (US)
Pages (from-to)495-499
Number of pages5
JournalJournal of Investigative Medicine
Volume57
Issue number3
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Fasting
Plasmas
Glucose
Medical problems
Angiotensin-Converting Enzyme Inhibitors
Aspirin
Hydroxymethylglutaryl CoA Reductases
Veterans
Islets of Langerhans
Metabolism
Hyperglycemia

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. / Sukhija, Rishi; Prayaga, Sastry; Marashdeh, Mohammad; Bursac, Zoran; Kakar, Priyanka; Bansal, Darpan; Sachdeva, Rajesh; Kesan, Sree Hari; Mehta, Jawahar L.

In: Journal of Investigative Medicine, Vol. 57, No. 3, 01.01.2009, p. 495-499.

Research output: Contribution to journalArticle

Sukhija, R, Prayaga, S, Marashdeh, M, Bursac, Z, Kakar, P, Bansal, D, Sachdeva, R, Kesan, SH & Mehta, JL 2009, 'Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients', Journal of Investigative Medicine, vol. 57, no. 3, pp. 495-499. https://doi.org/10.2310/JIM.0b013e318197ec8b
Sukhija, Rishi ; Prayaga, Sastry ; Marashdeh, Mohammad ; Bursac, Zoran ; Kakar, Priyanka ; Bansal, Darpan ; Sachdeva, Rajesh ; Kesan, Sree Hari ; Mehta, Jawahar L. / Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. In: Journal of Investigative Medicine. 2009 ; Vol. 57, No. 3. pp. 495-499.
@article{7141ccda8acf48aabbcf60ccd447801f,
title = "Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients",
abstract = "Background: The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) reduce serum cholesterol level and cardiovascular morbidity and mortality. However, the effect of statins on glucose metabolism is unclear. Some studies have suggested that statins may cause hyperglycemia by increasing calcium concentration in the islet cells leading to decrease in insulin release or by decreasing GLUT 4-mediated peripheral glucose uptake. Methods: We analyzed the data in 345,417 patients (mean age 61 ± 15 years, 94{\%} males, 6{\%} diabetic, 20{\%} statin users) from the Veterans Affairs VISN 16 database. We studied change in fasting plasma glucose (FPG) in this population over a mean time of 2 years between the first available measurement and the last measurement form the most recent recorded visit. Data were limited to patients who had 2 FPG measurements. Diagnosis of diabetes had to be present before the first FPG measurement. Results: Among patients without diabetes, FPG increased with statin use from 98 mg/dL to 105 mg/dL, and among nonstatin users, FPG increased from 97 mg/dL to 101 mg/dL (increase in FPG with statin use P < 0.0001). Among patients with diabetes, FPG increased with statin use from 102 mg/dL to 141 mg/dL, and among nonstatin users, FPG increased from 100 mg/dL to 129 mg/dL (increase in FPG with statin use; P < 0.0001). After adjustment for age and use of aspirin, β-blockers, and angiotensin-converting enzyme inhibitors, the change in FPG in nondiabetic statin users was 7 mg/dL (vs 5 mg/dL in nonstatin users, P < 0.0001) and for diabetic statin users it was 39 mg/dL (vs 32 in nonstatin users, P < 0.0001). Conclusions: Statin use is associated with a rise of FPG in patients with and without diabetes. This relationship between statin use and rise in FPG is independent of age and use of aspirin, β-blockers, and angiotensin-converting enzyme inhibitors.",
author = "Rishi Sukhija and Sastry Prayaga and Mohammad Marashdeh and Zoran Bursac and Priyanka Kakar and Darpan Bansal and Rajesh Sachdeva and Kesan, {Sree Hari} and Mehta, {Jawahar L.}",
year = "2009",
month = "1",
day = "1",
doi = "10.2310/JIM.0b013e318197ec8b",
language = "English (US)",
volume = "57",
pages = "495--499",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients

AU - Sukhija, Rishi

AU - Prayaga, Sastry

AU - Marashdeh, Mohammad

AU - Bursac, Zoran

AU - Kakar, Priyanka

AU - Bansal, Darpan

AU - Sachdeva, Rajesh

AU - Kesan, Sree Hari

AU - Mehta, Jawahar L.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Background: The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) reduce serum cholesterol level and cardiovascular morbidity and mortality. However, the effect of statins on glucose metabolism is unclear. Some studies have suggested that statins may cause hyperglycemia by increasing calcium concentration in the islet cells leading to decrease in insulin release or by decreasing GLUT 4-mediated peripheral glucose uptake. Methods: We analyzed the data in 345,417 patients (mean age 61 ± 15 years, 94% males, 6% diabetic, 20% statin users) from the Veterans Affairs VISN 16 database. We studied change in fasting plasma glucose (FPG) in this population over a mean time of 2 years between the first available measurement and the last measurement form the most recent recorded visit. Data were limited to patients who had 2 FPG measurements. Diagnosis of diabetes had to be present before the first FPG measurement. Results: Among patients without diabetes, FPG increased with statin use from 98 mg/dL to 105 mg/dL, and among nonstatin users, FPG increased from 97 mg/dL to 101 mg/dL (increase in FPG with statin use P < 0.0001). Among patients with diabetes, FPG increased with statin use from 102 mg/dL to 141 mg/dL, and among nonstatin users, FPG increased from 100 mg/dL to 129 mg/dL (increase in FPG with statin use; P < 0.0001). After adjustment for age and use of aspirin, β-blockers, and angiotensin-converting enzyme inhibitors, the change in FPG in nondiabetic statin users was 7 mg/dL (vs 5 mg/dL in nonstatin users, P < 0.0001) and for diabetic statin users it was 39 mg/dL (vs 32 in nonstatin users, P < 0.0001). Conclusions: Statin use is associated with a rise of FPG in patients with and without diabetes. This relationship between statin use and rise in FPG is independent of age and use of aspirin, β-blockers, and angiotensin-converting enzyme inhibitors.

AB - Background: The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) reduce serum cholesterol level and cardiovascular morbidity and mortality. However, the effect of statins on glucose metabolism is unclear. Some studies have suggested that statins may cause hyperglycemia by increasing calcium concentration in the islet cells leading to decrease in insulin release or by decreasing GLUT 4-mediated peripheral glucose uptake. Methods: We analyzed the data in 345,417 patients (mean age 61 ± 15 years, 94% males, 6% diabetic, 20% statin users) from the Veterans Affairs VISN 16 database. We studied change in fasting plasma glucose (FPG) in this population over a mean time of 2 years between the first available measurement and the last measurement form the most recent recorded visit. Data were limited to patients who had 2 FPG measurements. Diagnosis of diabetes had to be present before the first FPG measurement. Results: Among patients without diabetes, FPG increased with statin use from 98 mg/dL to 105 mg/dL, and among nonstatin users, FPG increased from 97 mg/dL to 101 mg/dL (increase in FPG with statin use P < 0.0001). Among patients with diabetes, FPG increased with statin use from 102 mg/dL to 141 mg/dL, and among nonstatin users, FPG increased from 100 mg/dL to 129 mg/dL (increase in FPG with statin use; P < 0.0001). After adjustment for age and use of aspirin, β-blockers, and angiotensin-converting enzyme inhibitors, the change in FPG in nondiabetic statin users was 7 mg/dL (vs 5 mg/dL in nonstatin users, P < 0.0001) and for diabetic statin users it was 39 mg/dL (vs 32 in nonstatin users, P < 0.0001). Conclusions: Statin use is associated with a rise of FPG in patients with and without diabetes. This relationship between statin use and rise in FPG is independent of age and use of aspirin, β-blockers, and angiotensin-converting enzyme inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=67650702822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650702822&partnerID=8YFLogxK

U2 - 10.2310/JIM.0b013e318197ec8b

DO - 10.2310/JIM.0b013e318197ec8b

M3 - Article

VL - 57

SP - 495

EP - 499

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 3

ER -